DESMOID TUMORS MARKET ANALYSIS

Market News

Global Desmoid Tumors Market: Key Developments

In May 2022, SpringWorks Therapeutics, a clinical-stage biopharmaceutical company, announced positive topline findings from the double-blind placebo controlled phase 3 DeFi trial (NCT03785964), assessing the use of nirogacestat as a treatment for adult patients with progressing desmoid tumors.

In September 2022, Ayala Pharmaceuticals announced that the U.S. Food and Drug Administration had granted a fast track designation to AL102 for the treatment of patients with progressing desmoid tumors.

Global Desmoid Tumors Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

Disruptions in routine and emergency medical care access and delivery have been observed during the COVID-19 pandemic. According to data published on the Centers for Disease Control and Prevention, in September 2020, an estimated 40.9% of the U.S. adults have avoided medical care during the pandemic because of concerns about COVID-19, including 12% who avoided urgent or emergency care and 31.5% who avoided routine care.  Many surgeries and different types of therapies have been postponed due to COVID-19. The desmoid tumor market had negative impact during the COVID-19 pandemic as the number of therapies were postponed or cancelled. According to data published on Elsevier in January 2021, in 2020, radiation therapy courses fell by 19·9% in April, 6·2% in May, and 11·6% in June compared with corresponding months in 2019 in the U.K. Moreover, COVID-19 has placed a tremendous strain on sustaining the clinical trails. According to the ClinicalTrials.gov report 2020, the challenges faced in conducting clinical research during the pandemic led to the termination of more than 2,000 registered clinical trails